Sun, Dec 21, 2014, 8:58 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Bergamo Acquisition Corp. Message Board

  • ripking99 ripking99 Jul 8, 2013 5:35 PM Flag

    VistaGen Provides Update on $36 Million Strategic Financing Agreement

    SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/28/13

    VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announced an update on the status of its strategic financing agreement with Autilion AG.

    Under the terms of the parties' April 2013 agreement, as amended, Autilion AG has committed to invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen common stock, at a price of $0.50 per share, in a series of closings ending on or before September 30, 2013. The parties have amended their agreement, completed a first closing and scheduled additional closings to occur in July, August and September 2013. As noted previously, the self-placed strategic financing does not include warrants or investment banking fees.

    Shawn K. Singh, VistaGen's Chief Executive Officer, stated, "I met with Autilion's team earlier this week, and we have been working closely with them since signing our agreement in April. We are confident and excited about completing this transformative financing. Building on the positive developments in our labs presented during the Annual Meetings of the Society of Toxicology and International Society of Stem Cell Research in March and this month, respectively, we look forward to accelerating our lead programs towards valuable outcomes for our shareholders."

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • lies lies nasty lil old lies tell me more

      Sentiment: Strong Sell

    • Shawn K. Singh, J.D., Chief Executive Officer, Director

      Mr. Singh has over 20 years of experience working with successful public and private biotechnology and pharmaceutical companies, a life sciences venture capital firm, and a profitable contract research and development organization (CRO), serving in numerous senior management roles. Prior to joining us as Chief Executive Officer in August 2009, Mr. Singh served as Managing Principal of Cato BioVentures, the venture capital affiliate of Cato Research, a global, full-service CRO for which he served as Chief Business Officer. Mr. Singh also served as President and Director of Echo Therapeutics (NASDAQ: ECTE), a medical device company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system for use in hospital critical care units and for people with diabetes, and as Chief Business Officer of SciClone Pharmaceuticals (NASDAQ: SCLN), a revenue-generating, profitable, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases, and cardiovascular, urological, respiratory, and central nervous system disorders. Mr. Singh began his career as a corporate finance attorney in the Silicon Valley offices of Morrison & Foerster LLP, an international law firm. He is a member of the State Bar of California. -

      Sentiment: Strong Buy

      • 6 Replies to ripking99
      • VSTA Has Head Start in Race to Develop New Drug Rescue Variants

        Sentiment: Strong Buy

      • Shawn K. Singh, VistaGen's Chief Executive Officer, stated, "I met with Autilion's team earlier this week, and we have been working closely with them since signing our agreement in April. We are confident and excited about completing this transformative financing. Building on the positive developments in our labs presented during the Annual Meetings of the Society of Toxicology and International Society of Stem Cell Research in March and this month, respectively, we look forward to accelerating our lead programs towards valuable outcomes for our shareholders."

        Sentiment: Strong Buy

      • Shawn K. Singh, J.D., Chief Executive Officer, Director

        Mr. Singh has over 20 years of experience working with successful public and private biotechnology and pharmaceutical companies, a life sciences venture capital firm, and a profitable contract research and development organization (CRO), serving in numerous senior management roles. Prior to joining us as Chief Executive Officer in August 2009, Mr. Singh served as Managing Principal of Cato BioVentures, the venture capital affiliate of Cato Research, a global, full-service CRO for which he served as Chief Business Officer. Mr. Singh also served as President and Director of Echo Therapeutics (NASDAQ: ECTE), a medical device company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system for use in hospital critical care units and for people with diabetes, and as Chief Business Officer of SciClone Pharmaceuticals (NASDAQ: SCLN), a revenue-generating, profitable, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases, and cardiovascular, urological, respiratory, and central nervous system disorders. Mr. Singh began his career as a corporate finance attorney in the Silicon Valley offices of Morrison & Foerster LLP, an international law firm. He is a member of the State Bar of California. -

        Sentiment: Strong Buy

      • VistaGen Therapeutics files 8-K updates BGMO financing deal

        Sentiment: Strong Buy

      • VSTA-Using mature human heart cells produced from pluripotent stem cells, They have leveraged their Human Clinical Trials in a TestTube™ platform to develop Car­dioSafe 3D™, a three-dimensional (3D) bioassay system for predicting the invivo cardiac effects of new drug candidates before they are tested in humans. VSTA plans to leverage CardioSafe 3D™ to build a pipeline of new, safer, drug rescue variants of promising drug candidates that have been “put on the shelf” by pharmaceutical companies because of toxicity concerns, despite positive efficacy data signaling their potential therapeutic and commercial benefits.

        Sentiment: Strong Buy

      • Has anyone checked out Shawn Singh`s and the rest of the prestigious management team`s bio on the VistaGen website. Singh had a career as a corporate finance attorney and is a member of the State Bar of California.

        Shawn K. Singh has built and sold many very large Biotech and Pharmaceutical companies, that are listed on the NASDAQ Stock Exchange ( I believe Shawn Singh before I believe anyone on the internet )

        Shawn K. Singh, VistaGen's Chief Executive Officer, stated, "I met with Autilion's team earlier this week, and we have been working closely with them since signing our agreement in April. We are confident and excited about completing this transformative financing.

        Sentiment: Strong Buy

 
BGMO.PK
0.010.00(0.00%)Oct 3 12:47 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.